Title:
MARKER FOR PREDICTING RESPONSIVENESS OF PANCREATIC CANCER PATIENT TO TREATMENT WITH ANTICANCER AGENT
Document Type and Number:
WIPO Patent Application WO/2022/075775
Kind Code:
A1
Abstract:
The present invention relates to a biomarker for predicting responsiveness to treatment with an anticancer agent and, more specifically, to a marker composition including a specific gene or a protein encoded thereby for predicting responsiveness to treatment with an anticancer agent in pancreatic cancer patients, a composition for predicting responsiveness to treatment with an anticancer agent, a kit for predicting responsiveness to treatment with an anticancer agent, and a method for providing information for predicting responsiveness to treatment with an anticancer agent. As a result of analyzing proteins within exosomes isolated from plasma of pancreatic cancer patients, the present inventors found that responsiveness to therapeutic effects of anticancer agents, specifically, a combined formulation of gemcitabine and nabpaclitaxel is significantly high depending on expression levels of a specific gene. Thus, the gene is expected to find advantageous applications in predicting efficacy of therapeutic effects of anticancer agents in pancreatic cancer patients.
Inventors:
YOON SEUNG BAE (KR)
SONG MEI YING (KR)
SONG MEI YING (KR)
Application Number:
PCT/KR2021/013801
Publication Date:
April 14, 2022
Filing Date:
October 07, 2021
Export Citation:
Assignee:
CATHOLIC UNIV KOREA IND ACADEMIC COOPERATION FOUNDATION (KR)
International Classes:
C12Q1/6886; G01N33/574; G01N33/68
Domestic Patent References:
| WO2016004387A1 | 2016-01-07 |
Foreign References:
| JP2009050189A | 2009-03-12 | |||
| US20160153053A1 | 2016-06-02 | |||
| US20190234951A1 | 2019-08-01 | |||
| JP2006061108A | 2006-03-09 |
Attorney, Agent or Firm:
ISIS IP LAW LLC (KR)
Download PDF: